Summit Therapeutics appoints Dr. Alessandra Cesano to Board of Directors, effective immediately

Summit Therapeutics Inc.

Dr. Cesano brings 25 years of oncology R&D experience; previously CMO at ESSA Pharma, NanoString, and Cleave Biosciences.
She played an instrumental role in development and approval of Vectibix® (panitumumab) for colorectal cancer.
Appointment aligns with Summit's plan to expand pipeline into oncology; she joins Compensation and Nominating Committees.
Dr. Cesano also serves on the board of Puma Biotechnology (NASDAQ: PBYI) and is independent under Nasdaq rules.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Alessandra Cesano

Director

SMMT · Summit Therapeutics Inc.

Effective: 2022-11-15
Filed: November 17, 2022, 6:59 PM ET

Effective on November 15, 2022, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved (i) the election of Dr. Alessandra Cesano, MD, PhD as a director of the Company and (ii) the appointment of Dr. Cesano to serve on the Compensation Committee and the Nominating and Corporate Governance Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Alessandra Cesano was elected as Director at Summit Therapeutics Inc..

Action: elected
Role: Director

Exact text from the filing

Effective on November 15, 2022, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved (i) the election of Dr. Alessandra Cesano, MD, PhD as a director of the Company and (ii) the appointment of Dr. Cesano to serve on the Compensation Committee and the Nominating and Corporate Governance Committee of the Board.

View on SEC.gov

Summit Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001599298-22-000123

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.